ED vs IBRX · P/E 18, rev $15.26B vs rev $113.3M
Consolidated Edison Inc (ED) versus Immunitybio Inc (IBRX) — a side-by-side from cached financials, not a winner call.
Consolidated Edison Inc (ED) is a utilities - regulated electric company listed on US.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Latest reported ED revenue for 2024-12-31 was $15.26B. Net income was $1.82B. Revenue was up 4.0% from 2023-12-31 to 2024-12-31. ED currently screens at market cap $36.02B and trailing P/E 18.3.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
ED currently screens at market cap $36.02B and trailing P/E 18.3. IBRX currently screens at market cap $7.88B.
Not investment advice. Open the ED and IBRX stock pages for the full models.
Not investment advice.